RC-1012

N/A

Report date: 2023/05/17 20:00:39

Base Information

Drug NameRC-1012
Drug Alias Name同种异体DNT细胞（瑞顺生物）RC1012RC-1012
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunomodulatorsT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, AcuteHematopoietic stem cell transplantation (HSCT)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRuichuang Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWyze Biotech Co LtdRuichuang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, AcuteHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A